RecruitingPhase 2NCT06824168
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission
Sponsor
Daiichi Sankyo
Enrollment
130 participants
Start Date
Jul 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Eligibility
Min Age: 18 Years
Inclusion Criteria12
- Adults ≥18 years of age or the minimum legal adult age (whichever is greater) on the day of signing the ICF (no upper limit of age).
- Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm based on the World Health Organization (WHO) 2008/2016 classification.
- Participant has confirmed FLT3-ITD-positive (≥0.05 SR or ≥5% VAF) activating mutation from initial diagnosis in bone marrow or peripheral blood as determined by a local institution's validated molecular testing.
- Participants must have confirmed, morphologically documented CR1, on the most recent BMA, based on the local laboratory results, performed within 28 days prior to C1D1 of maintenance therapy. Complete remission will be defined as \<5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer Rods), no evidence of extramedullary disease, and no leukemic blasts in the peripheral blood.
- Complete blood count recovery is required with absolute neutrophil count of more than 1.000 × 109/L and platelets more than 100 × 109/L (IWG criteria).27
- Participant must meet the following prior therapy requirements:
- Has received at least one cycle of induction therapy but no more than two to achieve CR1. The induction cycles can be the same regimen or different regimens and may contain conventional agents only (e.g., cytarabine + daunorubicin or idarubicin: "7 + 3" or "5 + 2"), or a combination with FLT3 inhibitors.
- Has not received more than four cycles of consolidation therapy. Regimens may contain conventional agents only.
- FLT3 inhibitors are permitted as part of the induction or consolidation treatment.
- Participants who received FLT3 inhibitors before enrollment in the trial will need a washout period of 14 days.
- Able to begin the maintenance phase within 60 days of D1 of the last consolidation cycle received.
- Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2.
Exclusion Criteria24
- Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (i.e., chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
- Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms.
- Prior treatment for AML, except for the following allowances:
- Induction and consolidation therapy, as previously described (inclusion criterion #5)
- Leukapheresis
- Hydroxyurea to treat hyperleukocytosis
- Cranial radiotherapy for central nervous system (CNS) leukostasis
- Prophylactic intrathecal chemotherapy
- Growth factor/cytokine support
- Participant had received allo-HSCT as part of AML treatment.
- Treatment with any strong or moderate CYP3A inducers within 2 weeks or 5 half-lives of randomization whichever is longer
- Uncontrolled or significant cardiovascular disease, including the following:
- QTcF interval \>450 ms (based on average of triplicate ECG at Screening)
- Diagnosed or suspected congenital long QT syndrome or known family history of congenital long QT syndrome
- History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes
- Participant has bradycardia of less than 50 beats per minute (bpm; as determined by central reading), unless the participant has a pacemaker
- History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
- Myocardial infarction within 6 months prior to screening
- Uncontrolled angina pectoris within 6 months prior to screening
- New York Heart Association Class 3 or 4 congestive heart failure
- LVEF ≤45% or institutional lower limit of normal
- Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg despite optimal medical management)
- Complete left or right bundle branch block
- Severe aortic stenosis
Interventions
DRUGQuizartinib High Dose
Participants in Arm 1 will receive oral daily higher dose of quizartinib,
DRUGQuizartinib Low Dose
Participants in Arm 2 will receive oral daily lower dose of quizartinib
Locations(58)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06824168
Related Trials
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT05554406216 locations
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
NCT065142614 locations
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146112 locations
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390331 locations
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393175 locations